SPECIAL FEATURES

CCR Translations

2121 Biomarkers for EGFR-Antagonist Response: In the Genes and on the Genes!
Hariharan Easwaran and Stephen B. Baylin
See article p. 2360

2124 Double Down for a Double Win
Pearl S. Huang
See article p. 2316

2127 Competing Risk Analyses: How Are They Different and Why Should You Care?
Rick Chappell
See article p. 2301

2130 Choosing Phase II Endpoints and Designs: Evaluating the Possibilities
Michael LeBlanc and Catherine Tangen
See article p. 2309

HUMAN CANCER BIOLOGY

Expression of Epstein-Barr Virus–Encoded Proteins in Extranodal NK/T-cell Lymphoma, Nasal Type (ENKL): Differences in Biologic and Clinical Behaviors of LMP1-Positive and -Negative ENKL
Naoko Kanemitsu, Yasushi Iseobe, Azuchi Masuda, Shuji Momose, Morhiro Higashi, Jun-ichi Tamaru, Koichi Sugimoto, and Norio Komatsu

Loss of Transforming Growth Factor Beta Type II Receptor Increases Aggressive Tumor Behavior and Reduces Survival in Lung Adenocarcinoma and Squamous Cell Carcinoma

Molecular Pathways

2133 Molecular Pathways: Digoxin Use and Estrogen-Sensitive Cancers—Risks and Possible Therapeutic Implications
Robert J. Biggar

2138 Molecular Pathways: Pathogenesis and Clinical Implications of Microbiome Alteration in Esophagitis and Barrett Esophagus
Liying Yang, Fritz Francois, and Zhiheng Pei

2145 Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment
Aiser A. Chanan-Khan, Jesús F. San Miguel, Sundar Jagannath, Heinz Ludwig, and Meletios A. Dimopoulos

CANCER THERAPY: PRECLINICAL

RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors

Stem-like Tumor-Initiating Cells Isolated from IL13Rα2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine–Redirected T Cells
Christine E. Brown, Renate Starr, Brenda Aguilar, Andrew F. Shami, Catalina Martinez, Massimo D’Apuzzo, Michael E. Barish, Stephen J. Forman, and Michael C. Jensen

Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma
Daruka Mahadevan, Amy Stejskal, Laurence S. Cooke, Ann Munziello, Carla Morales, Daniel O. Persky, Richard I. Fisher, Thomas P. Miller, and Wenqing Qi
First Evidence That γ-Tocotrienol Inhibits the Growth of Human Gastric Cancer and Chemosensitizes It to Capecitabine in a Xenograft Mouse Model through the Modulation of NF-κB Pathway

Kanjooormana A. Manu, Muthu K. Shanmugam, Lalitha Ramachandran, Feng Li, Chee Wui Fong, Alan Prem Kumar, Patrick Tan, and Gautam Sethi

The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin

Miguel Lemaire, Charlotte Fristedt, Prasoon Agarwal, Eline Menu, Els Van Valkenborgh, Elke De Bryune, Anders Osterborg, Peter Atadja, Ole Larsson, Magnus Axelsson, Ben Van Camp, Helena Jernberg-Wiklund, and Karin Vanderkerken

Improved Efficacy of Dendritic Cell–Based Immunotherapy by Cutaneous Laser Illumination

Xinyuan Chen, Qiyan Zeng, and Mei X. Wu
# Predictive Biomarkers and Personalized Medicine

### DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer

Kim Walter, Thomas Holcomb, Tom Januario, Pan Du, Marie Evangelista, Nithya Kartha, Leonardo Iniguez, Robert Soriano, Ling Hwu, Howard Stern, Zora Modrusan, Somasekar Seshagiri, Garret M. Hampton, Lukas C. Amler, Richard Bourgon, Robert L. Yauch, and David S. Shames

*See commentary p. 2121*

### Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth

Wilfred D. Stein, Julia Wilkerson, Sindy T. Kim, Xin Huang, Robert J. Motzer, Antonio Tito Fojo, and Susan E. Bates

---

### Correction

#### Correction: GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

---

### Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

Elizabeth A. Punnoose, Siminder Atwal, Weiquan Liu, Rajiv Baja, Bernard M. Fine, Brett G.M. Hughes, Rodney J. Hicks, Garret M. Hampton, Lukas C. Amler, Andrea Pirzkall, and Mark R. Lackner
ABOUT THE COVER

RAF265 greatly reduces the activation of MEK1 in melanoma patient tumors. Photomicrograph showing immunohistochemical localization of a remaining low level of active phospho-MEK1 (green) in a melanoma patient tumor that was treated with RAF265 after being implanted into a nude mouse. Nuclei are stained with DAPI and appear blue. 20X magnification. For details, see the article by Su and colleagues on page 2184 of this issue.